{"id":340452,"date":"2026-11-05T13:17:14","date_gmt":"2026-11-05T07:47:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340452"},"modified":"2026-11-05T13:17:14","modified_gmt":"2026-11-05T07:47:14","slug":"cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/","title":{"rendered":"3 Cardiac and Chronic Care Drug Maker, Powertrain Components Maker and Digital Engineering Firm Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies: ROE of 11.8% to 25.5% and FY22 to FY26 revenue CAGR of 7.8% to 38.3%. Prices as of 4 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three cardiac drug, powertrain and digital stocks to watch are Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Their return on equity ranges from 11.8% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.8% to 38.3%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Craftsman Automation has the fastest revenue growth at 38.3% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Cardiac drug, powertrain and digital stocks let investors follow companies that serve a growing part of the Indian economy. Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies cover a cardiac and chronic care drug maker, a powertrain components maker and a digital engineering firm.<\/p>\n<p>This list covers three cardiac drug, powertrain and digital stocks with complete current figures: Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#What_Are_Cardiac_Drug_Powertrain_and_Digital_Stocks\" title=\"What Are Cardiac Drug, Powertrain and Digital Stocks?\">What Are Cardiac Drug, Powertrain and Digital Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Cardiac_Drug_Powertrain_and_Digital_Stocks_at_a_Glance\" title=\"Cardiac Drug, Powertrain and Digital Stocks at a Glance\">Cardiac Drug, Powertrain and Digital Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Why_Do_Cardiac_Drug_Powertrain_and_Digital_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Cardiac Drug, Powertrain and Digital Stocks Have a Strong Roadmap in India?\">Why Do Cardiac Drug, Powertrain and Digital Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Why_Torrent_Pharmaceuticals_Features_Among_These_Cardiac_Drug_Powertrain_and_Digital_Stocks\" title=\"Why Torrent Pharmaceuticals Features Among These Cardiac Drug, Powertrain and Digital Stocks\">Why Torrent Pharmaceuticals Features Among These Cardiac Drug, Powertrain and Digital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Why_Craftsman_Automation_Features_Among_These_Cardiac_Drug_Powertrain_and_Digital_Stocks\" title=\"Why Craftsman Automation Features Among These Cardiac Drug, Powertrain and Digital Stocks\">Why Craftsman Automation Features Among These Cardiac Drug, Powertrain and Digital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Why_Zensar_Technologies_Features_Among_These_Cardiac_Drug_Powertrain_and_Digital_Stocks\" title=\"Why Zensar Technologies Features Among These Cardiac Drug, Powertrain and Digital Stocks\">Why Zensar Technologies Features Among These Cardiac Drug, Powertrain and Digital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Torrent_Pharmaceuticals_vs_Craftsman_Automation_vs_Zensar_Technologies_on_Key_Financials\" title=\"Torrent Pharmaceuticals vs Craftsman Automation vs Zensar Technologies on Key Financials\">Torrent Pharmaceuticals vs Craftsman Automation vs Zensar Technologies on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Key_Risks_to_Check_Before_Investing_in_Cardiac_Drug_Powertrain_and_Digital_Stocks\" title=\"Key Risks to Check Before Investing in Cardiac Drug, Powertrain and Digital Stocks\">Key Risks to Check Before Investing in Cardiac Drug, Powertrain and Digital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Final_Thoughts_on_Cardiac_Drug_Powertrain_and_Digital_Stocks\" title=\"Final Thoughts on Cardiac Drug, Powertrain and Digital Stocks\">Final Thoughts on Cardiac Drug, Powertrain and Digital Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#What_are_cardiac_drug_powertrain_and_digital_stocks\" title=\"What are cardiac drug, powertrain and digital stocks?\">What are cardiac drug, powertrain and digital stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Which_cardiac_drug_powertrain_and_digital_stocks_are_covered_in_this_list\" title=\"Which cardiac drug, powertrain and digital stocks are covered in this list?\">Which cardiac drug, powertrain and digital stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Why_do_cardiac_drug_powertrain_and_digital_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do cardiac drug, powertrain and digital stocks have a strong future roadmap in India?\">Why do cardiac drug, powertrain and digital stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#How_has_Torrent_Pharmaceuticals_performed_financially\" title=\"How has Torrent Pharmaceuticals performed financially?\">How has Torrent Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#How_has_Craftsman_Automation_performed_financially\" title=\"How has Craftsman Automation performed financially?\">How has Craftsman Automation performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#How_has_Zensar_Technologies_performed_financially\" title=\"How has Zensar Technologies performed financially?\">How has Zensar Technologies performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#What_risks_should_investors_check_before_buying_cardiac_drug_powertrain_and_digital_stocks\" title=\"What risks should investors check before buying cardiac drug, powertrain and digital stocks?\">What risks should investors check before buying cardiac drug, powertrain and digital stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital-engineering-firm-stocks-roadmap-lookout-list\/#Is_this_list_of_cardiac_drug_powertrain_and_digital_stocks_investment_advice\" title=\"Is this list of cardiac drug, powertrain and digital stocks investment advice?\">Is this list of cardiac drug, powertrain and digital stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Cardiac_Drug_Powertrain_and_Digital_Stocks\"><\/span><strong>What Are Cardiac Drug, Powertrain and Digital Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cardiac drug, powertrain and digital stocks are listed companies that sell cardiac and chronic care medicines, make powertrain and aluminium components for vehicles and industry, and provide digital engineering and cloud services to global clients. Their earnings depend on prescriptions, vehicle output and client technology budgets.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cardiac_Drug_Powertrain_and_Digital_Stocks_at_a_Glance\"><\/span><strong>Cardiac Drug, Powertrain and Digital Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/torntpharm\/torrent-pharmaceuticals-ltd-share-price-today\">Torrent Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,738.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">173,079<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">80.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.79<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/craftsman\/craftsman-automation-ltd-share-price-today\">Craftsman Automation<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,685<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28,768<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">61.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.11<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/zensartech\/zensar-technologies-ltd-share-price-today\">Zensar Technologies<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">533<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,686<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Zensar Technologies trades at a P\/E below the industry P\/E, while Torrent Pharmaceuticals and Craftsman Automation trade above it, which reflects the growth the market already expects. Readers comparing cardiac drug, powertrain and digital stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cardiac drug, powertrain and digital stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Cardiac_Drug_Powertrain_and_Digital_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Cardiac Drug, Powertrain and Digital Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cardiac drug, powertrain and digital stocks have a strong roadmap in India because rising chronic care medicine use, steady vehicle output and growing client technology spending keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Cardiac drugs.<\/strong> Chronic care medicines see steady use.<\/li>\n<li><strong>Powertrain parts.<\/strong> Vehicle makers need dependable components.<\/li>\n<li><strong>Digital services.<\/strong> Global clients modernise systems.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Torrent_Pharmaceuticals_Features_Among_These_Cardiac_Drug_Powertrain_and_Digital_Stocks\"><\/span><strong>Why Torrent Pharmaceuticals Features Among These Cardiac Drug, Powertrain and Digital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the cardiac drug, powertrain and digital stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.<\/p>\n<p>Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<p><strong>What to watch:<\/strong> Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Craftsman_Automation_Features_Among_These_Cardiac_Drug_Powertrain_and_Digital_Stocks\"><\/span><strong>Why Craftsman Automation Features Among These Cardiac Drug, Powertrain and Digital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma, auto part and technology shares on this list, Craftsman Automation, based in Coimbatore, makes powertrain components, aluminium products and industrial and engineering products such as storage solutions and machine building.<\/p>\n<p>In the June 2026 quarter, revenue grew 37.2% year on year to Rs 2,455 crore, while net profit rose 116.3% to Rs 151 crore. Revenue rose from Rs 2,224 crore in FY22 to Rs 8,131 crore in FY26, a compound annual growth rate of 38.3%.<\/p>\n<p>Net profit grew from Rs 163 crore in FY22 to Rs 384 crore in FY26, which works out to a compound annual growth rate of 23.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 1.11 and a market capitalisation of Rs 28,768 crore. The stock trades at a P\/E of 61.9, above the industry P\/E of 36.1.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding capacity across powertrain, aluminium and industrial divisions to serve customers in several sectors. A diversified base reduces dependence on any one product line.<\/p>\n<p><strong>What to watch:<\/strong> Follow capacity additions, aluminium division growth and demand from industrial customers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Zensar_Technologies_Features_Among_These_Cardiac_Drug_Powertrain_and_Digital_Stocks\"><\/span><strong>Why Zensar Technologies Features Among These Cardiac Drug, Powertrain and Digital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Zensar Technologies, an RPG group company, offers digital engineering, cloud and experience services to clients across financial services, retail and manufacturing.<\/p>\n<p>The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P\/E of 15.1, below the industry P\/E of 17.5.<\/p>\n<p>Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.<\/p>\n<p><strong>What to watch:<\/strong> Follow client concentration and growth in large accounts.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Torrent_Pharmaceuticals_vs_Craftsman_Automation_vs_Zensar_Technologies_on_Key_Financials\"><\/span><strong>Torrent Pharmaceuticals vs Craftsman Automation vs Zensar Technologies on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three cardiac drug, powertrain and digital stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,705<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,886<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,138<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Craftsman Automation<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,224<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,131<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">384<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Zensar Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,382<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,921<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">775<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Craftsman Automation shows the fastest revenue growth with a 38.3% compound annual rate. A useful habit with cardiac drug, powertrain and digital stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,141<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,909<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">56.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Craftsman Automation<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,789<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,455<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Zensar Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,442<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,566<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Cardiac_Drug_Powertrain_and_Digital_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Cardiac Drug, Powertrain and Digital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these cardiac drug, powertrain and digital stocks, the main points are: Long-term pharma, auto part and technology shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter cardiac drug, powertrain and digital stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Cardiac_Drug_Powertrain_and_Digital_Stocks\"><\/span><strong>Final Thoughts on Cardiac Drug, Powertrain and Digital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cardiac drug, powertrain and digital stocks reward investors who follow demand trends, order books and margins together. Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies each have a clear plan to grow. Based on the 4 November 2026 close, Torrent Pharmaceuticals trades at Rs 4,738.5, Craftsman Automation at Rs 10,685 and Zensar Technologies at Rs 533. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these cardiac drug, powertrain and digital stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track cardiac drug, powertrain and digital stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_cardiac_drug_powertrain_and_digital_stocks\"><\/span><strong>What are cardiac drug, powertrain and digital stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cardiac drug, powertrain and digital stocks are listed companies that sell cardiac and chronic care medicines, make powertrain and aluminium components for vehicles and industry, and provide digital engineering and cloud services to global clients. Their earnings depend on prescriptions, vehicle output and client technology budgets. This list looks at three of them, Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_cardiac_drug_powertrain_and_digital_stocks_are_covered_in_this_list\"><\/span><strong>Which cardiac drug, powertrain and digital stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Based on the 4 November 2026 close, Torrent Pharmaceuticals traded at Rs 4,738.5, Craftsman Automation at Rs 10,685 and Zensar Technologies at Rs 533. Their return on equity ranges from 11.8% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.8% to 38.3%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_cardiac_drug_powertrain_and_digital_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do cardiac drug, powertrain and digital stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cardiac drug, powertrain and digital stocks have a strong roadmap in India because rising chronic care medicine use, steady vehicle output and growing client technology spending keep widening the market for these companies. The main drivers are as follows. Cardiac drugs. Chronic care medicines see steady use. Powertrain parts. Vehicle makers need dependable components. Digital services. Global clients modernise systems. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Torrent_Pharmaceuticals_performed_financially\"><\/span><strong>How has Torrent Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Craftsman_Automation_performed_financially\"><\/span><strong>How has Craftsman Automation performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,224 crore in FY22 to Rs 8,131 crore in FY26, a compound annual growth rate of 38.3%. Net profit grew from Rs 163 crore in FY22 to Rs 384 crore in FY26, which works out to a compound annual growth rate of 23.9%. In the June 2026 quarter, revenue grew 37.2% year on year to Rs 2,455 crore, while net profit rose 116.3% to Rs 151 crore. The company has a return on equity of 11.8%, a debt to equity ratio of 1.11 and a market capitalisation of Rs 28,768 crore. The stock trades at a P\/E of 61.9, above the industry P\/E of 36.1. Looking ahead, the company is adding capacity across powertrain, aluminium and industrial divisions to serve customers in several sectors. A diversified base reduces dependence on any one product line.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Zensar_Technologies_performed_financially\"><\/span><strong>How has Zensar Technologies performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P\/E of 15.1, below the industry P\/E of 17.5. Looking ahead, strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_cardiac_drug_powertrain_and_digital_stocks\"><\/span><strong>What risks should investors check before buying cardiac drug, powertrain and digital stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying cardiac drug, powertrain and digital stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_cardiac_drug_powertrain_and_digital_stocks_investment_advice\"><\/span><strong>Is this list of cardiac drug, powertrain and digital stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are cardiac drug, powertrain and digital stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cardiac drug, powertrain and digital stocks are listed companies that sell cardiac and chronic care medicines, make powertrain and aluminium components for vehicles and industry, and provide digital engineering and cloud services to global clients. Their earnings depend on prescriptions, vehicle output and client technology budgets. This list looks at three of them, Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which cardiac drug, powertrain and digital stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Based on the 4 November 2026 close, Torrent Pharmaceuticals traded at Rs 4,738.5, Craftsman Automation at Rs 10,685 and Zensar Technologies at Rs 533. Their return on equity ranges from 11.8% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.8% to 38.3%.\"}},{\"@type\":\"Question\",\"name\":\"Why do cardiac drug, powertrain and digital stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cardiac drug, powertrain and digital stocks have a strong roadmap in India because rising chronic care medicine use, steady vehicle output and growing client technology spending keep widening the market for these companies. The main drivers are as follows. Cardiac drugs. Chronic care medicines see steady use. Powertrain parts. Vehicle makers need dependable components. Digital services. Global clients modernise systems. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Torrent Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.\"}},{\"@type\":\"Question\",\"name\":\"How has Craftsman Automation performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,224 crore in FY22 to Rs 8,131 crore in FY26, a compound annual growth rate of 38.3%. Net profit grew from Rs 163 crore in FY22 to Rs 384 crore in FY26, which works out to a compound annual growth rate of 23.9%. In the June 2026 quarter, revenue grew 37.2% year on year to Rs 2,455 crore, while net profit rose 116.3% to Rs 151 crore. The company has a return on equity of 11.8%, a debt to equity ratio of 1.11 and a market capitalisation of Rs 28,768 crore. The stock trades at a P\/E of 61.9, above the industry P\/E of 36.1. Looking ahead, the company is adding capacity across powertrain, aluminium and industrial divisions to serve customers in several sectors. A diversified base reduces dependence on any one product line.\"}},{\"@type\":\"Question\",\"name\":\"How has Zensar Technologies performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P\/E of 15.1, below the industry P\/E of 17.5. Looking ahead, strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying cardiac drug, powertrain and digital stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying cardiac drug, powertrain and digital stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of cardiac drug, powertrain and digital stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cardiac Drug, Powertrain and Digital Stocks with a strong future roadmap: Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Compare price, valuation, return on equity and revenue growth as of 4 November 2026.<\/p>\n","protected":false},"author":38,"featured_media":340451,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[20593,3803,20591,20594,7057,20595,20592,13963,6974],"class_list":["post-340452","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-auto-part-and-technology-shares","tag-best-stocks","tag-cardiac-drug","tag-chronic-care","tag-craftsman-automation","tag-engine-block-and-cloud-stocks","tag-powertrain-and-digital-stocks","tag-torrent-pharmaceuticals","tag-zensar-technologies"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340451"],"rank_math_title":["Cardiac Drug, Powertrain and Digital Stocks"],"rank_math_description":["Compare 3 cardiac drug, powertrain and digital stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 4 Nov 2026."],"rank_math_focus_keyword":["cardiac drug, powertrain and digital stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-cardiac-and-chronic-care-drug-maker-powertrain-components-maker-and-digital.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340452"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340452\/revisions"}],"predecessor-version":[{"id":340453,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340452\/revisions\/340453"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340451"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}